GENELUX Corp — Investor Relations & Filings

Genelux Corporation is a clinical-stage biopharmaceutical company developing next-generation oncolytic viral immunotherapies for patients with aggressive and difficult-to-treat solid tumors. The company's technology is based on a proprietary discovery platform, CHOICE™, which utilizes an engineered vaccinia virus (VACV) as its backbone. This approach creates "off-the-shelf" therapeutics designed to selectively replicate within and kill cancer cells, stimulating a robust, patient-specific anti-tumor immune response. The lead product candidate, Olvi-Vec, is a modified vaccinia virus administered systemically. It is currently being evaluated in a registrational Phase 3 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer. The company is also preparing for a Phase 2 trial in recurrent non-small cell lung cancer.